OBJECTIVES: Eosinophilic Esophagitis (EoE) is an inflammatory disorder that can have an impact on quality of life in individuals. The psychometric properties of the Dysphagia Symptom Questionnaire (DSQ) were assessed in a Phase 2, randomized, double-blind, placebo controlled study of oral budesonide suspension with an open-label extension program. METHODS: The evaluation focused on three items of the DSQ. Psychometric data were analyzed against the FDA guidance and included item level analysis as well as score validation including floor/ceiling, item discrimination, construct validity (concurrent validity and known group’s method), test-retest reliability, responsiveness, and calculation of minimally important differences (MID). RESULTS: Patients were 69% male, 62% age ≥18, 95% white.  Test-retest reliability was strong (r=0.82). Floor/ceiling levels were below the criteria (≤9%) for all items (range 6.5-8.6%).  There was strong item discrimination with 98.1% of patients indicating dysphagia in the quartile of DSQ scores.  Physician’s global ratings of severity and EoE symptom scores were consistent with monotonically increasing DSQ scores.  Anchor-based MIDs were 6.5 “a little better” and 13.5 “better” respectively. CONCLUSIONS: The DSQ is a reliable and valid measure able to clinically discriminate patients along the continuum of dysphagia severity.